Citius Pharmaceuticals, Inc. (CTXR) Stock Score, Valuation & Financial Research

Citius Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CTXR

Citius Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.53. These figures are a research snapshot, not a buy or sell recommendation.

What Citius Pharmaceuticals, Inc. does

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Company business and revenue

Research reporting period: 2025-09-30. A research update is not a new financial filing.

How the company makes money

Citius Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products. The company operates through a model of advancing therapeutic candidates through clinical trials and regulatory approval processes, with revenue generation dependent on the successful commercialization of its products, such as LYMPHIR, which launched in December 2025.

Products and services

  • The company's portfolio includes LYMPHIR (denileukin diftitox), a targeted immunotherapy for cutaneous T-cell lymphoma, and late-stage pipeline candidates including Mino-Lok and Halo-Lido.

Brands and product families

  • LYMPHIR — A targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma. Source

Customer types

Hospitals and healthcare providers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its pharmaceutical products; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Novellus — A license agreement where Novellus remits 50% of revenue involving the original cell line included in the licensed technology to NoveCite, a subsidiary of Citius. Source

Business strengths to evaluate

  • Focus on first-in-class critical care products with intellectual property and regulatory exclusivity protection. Source

Business risks and research considerations

  • History of operating losses and the need for additional capital to fund operations and clinical development. Source
  • Dependence on third-party manufacturers and clinical research organizations. Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CTXR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.53
Market capitalization:
14.58M (currency not supplied)
Revenue:
USD 7.11M
Net income:
USD -46.27M
Free cash flow:
USD -26.55M
Cash:
USD 17.01M
Total debt:
USD 7.18M
EPS:
USD -2.11

What stands out

  • Free cash flow is USD -26.55M, negative for the stored period.
  • The balance sheet shows USD 17.01M of cash versus USD 7.18M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -373.7% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -651.3% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 9.83M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CTXR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CTXR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CTXR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CTXR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CTXR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CTXR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.